Gilead Exercises Option on Assembly Bio's Herpes Programs, Signals Pipeline Shift

Event summary

  • Gilead Sciences has exercised its option to license Assembly Biosciences’ helicase-primase inhibitor programs (ABI-1179 and ABI-5366) for recurrent genital herpes.
  • Gilead will pay Assembly Bio $35 million, reflecting a $45 million option fee, with $10 million already credited from prior funding.
  • Assembly Bio is eligible for up to $330 million in regulatory and commercial milestones and tiered royalties.
  • The deal represents the first program advanced under a 2023 R&D collaboration between the two companies.
  • ABI-1179 and ABI-5366 have shown promising Phase 1b data, demonstrating antiviral activity and potential for once-weekly oral dosing.

The big picture

Gilead's move underscores its ongoing strategy to bolster its antiviral pipeline through external collaborations, particularly in areas with unmet medical needs. The deal, valued at $35 million upfront with a potential $330 million in milestones, highlights the continued interest in novel therapies for recurrent genital herpes, a chronic condition affecting millions. This acquisition also signals a potential shift in Gilead’s development focus towards long-acting oral therapies, a trend gaining traction in the antiviral space.

What we're watching

Clinical Trial
The success of ABI-1179 and ABI-5366 will hinge on Phase 2/3 trial results, given the lack of new HSV therapies in over two decades; failure to demonstrate efficacy could significantly impact Gilead's antiviral pipeline strategy.
Financial Impact
Assembly Bio’s ability to secure and manage the $330 million in potential milestone payments will be crucial for its continued operations and pipeline development, especially given the option to share costs and profits.
Strategic Alignment
How Gilead integrates these programs into its existing antiviral portfolio and prioritizes their development relative to other pipeline assets will reveal the company’s long-term commitment to the HSV therapeutic area.